注释ID

827864375

变量_单倍型

CYP2A6*1A, CYP2A6*2, CYP2A6*4A, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*35

基因

CYP2A6

药物名称(英)

letrozole

药物名称(中)

来曲唑

PMID

21975350

类型

Metabolism/PK

含义

yes

记事

Patients were grouped into normal (n = 200; *1/*1), intermediate (IM) (n = 40; *1/*9 and *1/*12), and slow (n = 21; *1/26, *1/35, *20/*23, *9/*9, *1/*4E, *1/*2, *17/*17, *1/*17, *17/*35, *2/*9, *9/*12) metabolizer groups. P-value given here is for slow or intermediate metabolizers compared normal metabolizers [stat_test: kruskal-wallis post hoc test]. CYP2A6*1/*26 and CYP2A6*1/*35 genotypes was consistent with normal metabolizers of letrozole rather than slow metabolizers. CYP2A6*12 was associated more with slow metabolizers than with intermediate metabolizers. CYP2A6*1/*26 and CYP2A6*1/*35(n = 1 each) were excluded from the analysis and CYP2A6*1/*12 (n = 11) were analyzed on the assumption that they related to slow metabolizers, which strengthened the analysis. Please note that this paper originally identified the *4E allele, which has been reassigned to *4 by PharmVar.

专家论述

CYP2A6 *1A/*17 + *20/*23 + *9/*9 + *1A/*4A + *1A/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1A/*9 + *1A/*12 are associated with decreased clearance of letrozole in women with Breast Neoplasms as compared to CYP2A6 *1A/*1A.

等位基因

*1A/*17 + *20/*23 + *9/*9 + *1A/*4A + *1A/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1A/*9 + *1A/*12

专家评论

备注

变体注释摘要

id	研究类型	特征类型
17932	cohort	Study Cohort
17931	cohort	Study Cohort